anacardic acid has been researched along with sp 100030 in 1 studies
| Studies (anacardic acid) | Trials (anacardic acid) | Recent Studies (post-2010) (anacardic acid) | Studies (sp 100030) | Trials (sp 100030) | Recent Studies (post-2010) (sp 100030) |
|---|---|---|---|---|---|
| 177 | 1 | 120 | 17 | 0 | 6 |
| Protein | Taxonomy | anacardic acid (IC50) | sp 100030 (IC50) |
|---|---|---|---|
| Transcription factor AP-1 | Homo sapiens (human) | 0.05 | |
| Cyclic AMP-dependent transcription factor ATF-1 | Homo sapiens (human) | 0.05 | |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | 0.05 | |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | 0.05 | |
| Transcription factor p65 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CZ; Guo, H; Hu, X; Klumpp-Thomas, C; Michael, SG; Shen, M; Shinn, P; Xu, M; Zheng, W; Zhu, W | 1 |
1 other study(ies) available for anacardic acid and sp 100030
| Article | Year |
|---|---|
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
Topics: | 2020 |